<DOC>
	<DOCNO>NCT01588782</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , safety , potential drug-drug interaction strong inhibitor CYP3A4 ( ie , ketoconazole ) co-administered abiraterone acetate healthy adult men .</brief_summary>
	<brief_title>A Study Assess Effect Ketoconazole Pharmacokinetics Abiraterone Following Administration Abiraterone Acetate Tablets Healthy Adult Men</brief_title>
	<detailed_description>This non-randomized ( individual assign chance study treatment ) , open-label ( individual know identity study treatment ) , 2-period , sequential-design , drug-drug interaction study abiraterone acetate ketoconazole approximately 20 healthy adult men . This study consist screen period follow open-label treatment phase consist 2 treatment period . Successive drug administration separate washout period least 10 day . All individual receive study treatment sequence . Period 1 ( Days 1 4 ) consist single oral dose 1000 mg abiraterone acetate tablet Day 1 . Period 2 ( Days 11 17 ) consist daily oral dose 400 mg ketoconazole tablet Days 11 16 administration single dose 1000 mg abiraterone acetate Day 14 . Serial pharmacokinetic ( study body drug ) sample collect treatment period detail protocol . Safety monitor continuously time informed consent sign end study .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Body mass index ( BMI ) 18 30 kg/m2 , inclusive History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>JNJ-589485</keyword>
	<keyword>JNJ-212082</keyword>
	<keyword>Ketoconazole</keyword>
</DOC>